



Edgar Filing: IsoRay, Inc. - Form SD

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2017.

---

## **Introduction**

This Specialized Disclosure Report on Form SD (“Form SD”) of IsoRay, Inc. (“IsoRay,” the “Company,” or “we”) for the year ended December 31, 2017 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). Numerous terms in this Form SD are defined in the Rule and the reader is referred to that source and to SEC Release No. 34-67716 issued by the Securities and Exchange Commission on August 22, 2012 for such definitions.

We are a medical technology company that develops, manufactures, and markets seed brachytherapy and medical radioisotope applications for various cancers. Our brachytherapy seeds contain a small amount of gold that is necessary to the functionality or production of those products. Our brachytherapy seeds are manufactured in IsoRay’s own facility. Although our brachytherapy seeds contain a small amount of gold, IsoRay does not purchase ore or unrefined conflict minerals from mines and is many steps removed in the supply chain from the mining of the conflict minerals. We historically have purchased the gold used in our products from a single supplier. This supplier is in the best position in the total supply chain to know the origin of the gold we use. We rely on this supplier to assist with our reasonable country of origin inquiry for the gold contained in the materials which it supplies to us.

## **Section 1- Conflict Minerals Disclosure**

### **Item 1.01 Conflict Minerals Disclosure and Report**

#### **Conflict Minerals Disclosure**

This Form SD of IsoRay, Inc. is filed pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January 1, 2017 to December 31, 2017.

The Company manufactures products for which a Conflict Mineral, gold, is necessary to the functionality or production of those products. However, the Company did not purchase gold from any source between January 1, 2017 and December 31, 2017. The Company conducted a good faith reasonable country of origin inquiry for the 2015 calendar year, the last year in which it purchased gold, regarding the Conflict Minerals. The good faith reasonable country of origin inquiry was reasonably designed to determine whether any of the Conflict Minerals originated in the Covered Countries and whether any of the Conflict Minerals may be from recycled or scrap sources.

For the 2015 reporting year, we contacted our single direct supplier of gold to obtain country of origin information for the gold in our brachytherapy seeds. Our supplier certified that all gold purchased in 2015 was from sources outside of the Covered Countries. As the Company purchased no gold in 2017, no additional inquiry was conducted.

### **Conclusion**

Based on this reasonable country of origin inquiry, the Company determined that it has no reason to believe that the Conflict Minerals may have originated in the Covered Countries. Therefore, the Company is not required to provide a conflict minerals report.

### **Website Disclosure**

This Form SD is publicly available at [www.isoray.com](http://www.isoray.com) as well as the SEC's EDGAR database at [www.sec.gov](http://www.sec.gov). The content of any website referred to in this Form SD is included for general information only and is not incorporated by reference in this Form SD.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

IsoRay, Inc.

By: /s/ Thomas C. LaVoy     May 25, 2018  
Thomas C. LaVoy, CEO (DATE)